1-4 of 4
B. M. Sandmaier
Close
Sort by
Journal Articles

Efficacy of Nonmyeloablative Hematopoietic Cell Transplant (HCT) in Secondary Myelodysplastic Syndrome (MDS) and Its Impact on the Primary Disease.

F. Kerbauy, M. Maris, B. Storer, D. Maloney, D. Niederwieser, E. Agura, M. Pulsipher, T. Chauncey, R. Maziarz, S. Forman, A. Langston, J. Wade, B. Scott, J. Deeg, R. Storb, B. M. Sandmaier
Journal: Blood
Blood (2005) 106 (11): 792.
https://doi.org/10.1182/blood.V106.11.792.792
Published: 2005
Journal Articles

Feasibility and Toxicity of Nonmyeloablative Hematopoietic Cell Transplantation (HCT) with or without Imatinib for Philadelphia Chromosome (Ph+) Acute Lymphoblastic Leukemia (ALL).

L. Norasetthada, M. B. Maris, B. M. Sandmaier, D. G. Maloney, G. Georges, B. Druker, J. Radich, R. Storb
Journal: Blood
Blood (2004) 104 (11): 5056.
https://doi.org/10.1182/blood.V104.11.5056.5056
Published: 2004
Journal Articles

HLA-Matched Related (MRD) or Unrelated Donor (URD) Non-Myeloablative Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Refractory and Relapsed Aggressive Non Hodgkin Lymphoma (NHL).

L. Norasetthada, M. B. Maris, B. M. Sandmaier, T. Gooley, S. Forman, E. Agura, R. T. Maziarz, J. Shizuru, D. Niederwieser, R. Storb, D. G. Maloney
Journal: Blood
Blood (2004) 104 (11): 2307.
https://doi.org/10.1182/blood.V104.11.2307.2307
Published: 2004
Journal Articles

Unrelated Donor Peripheral Blood Stem Cell (PBSC) Transplantation Using Nonmyeloablative Conditioning and Mycophenolate Mofetil (MMF) TID Results in High Engraftment Rates.

Michael B. Maris, MD, B. M. Sandmaier, MD, B. Storer, PhD, J. Shizuru, MD, PhD, D. Maloney, MD, PhD, E. Agura, MD, PhD, D. Niederwieser, MD, M. Pulsipher, MD, R. T. Maziarz, MD, P. McSweeney, MD, J. Wade, MD, A. Langston, MD, T. Chauncey, MD, B. Bruno, MD, A. Woolfrey, MD, M.T. Little, PhD, K. Blume, MD, R. Storb, MD
Journal: Blood
Blood (2004) 104 (11): 1818.
https://doi.org/10.1182/blood.V104.11.1818.1818
Published: 2004